Among hematologic tumors, loss-of-function mutations in TMEM30A have been identified in approximately 5%–11% of patients with DLBCL, and among a cohort of newly diagnosed patients, this mutation was correlated with improved response to standard R-CHOP therapy.49 This evidence concerns the gene CDC50A and diffuse large B-cell lymphoma.